These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36746739)

  • 1. Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.
    Erdem R; De Coster I; Withanage K; Mercer LD; Marchant A; Taton M; Cools N; Lion E; Cassels F; Higgins D; Ivinson K; Locke E; Mahmood K; Wright PF; Gast C; White JA; Ackerman ME; Konopka-Anstadt JL; Mainou BA; Van Damme P
    Vaccine; 2023 Mar; 41(10):1657-1667. PubMed ID: 36746739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.
    Crothers JW; Ross Colgate E; Cowan KJ; Dickson DM; Walsh M; Carmolli M; Wright PF; Norton EB; Kirkpatrick BD
    Vaccine; 2022 Apr; 40(19):2705-2713. PubMed ID: 35367069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
    Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
    Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.
    Norton EB; Bauer DL; Weldon WC; Oberste MS; Lawson LB; Clements JD
    Vaccine; 2015 Apr; 33(16):1909-15. PubMed ID: 25765967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.
    Brickley EB; Wieland-Alter W; Connor RI; Ackerman ME; Boesch AW; Arita M; Weldon WC; O'Ryan MG; Bandyopadhyay AS; Wright PF
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S42-S50. PubMed ID: 30376086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine.
    Zhao T; Li J; Shi H; Ye H; Ma R; Fu Y; Liu X; Li G; Yang X; Zhao Z; Yang J
    Hum Vaccin Immunother; 2021 Aug; 17(8):2560-2567. PubMed ID: 33848232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.
    John J; Giri S; Karthikeyan AS; Iturriza-Gomara M; Muliyil J; Abraham A; Grassly NC; Kang G
    Lancet; 2014 Oct; 384(9953):1505-12. PubMed ID: 25018120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.
    Brickley EB; Strauch CB; Wieland-Alter WF; Connor RI; Lin S; Weiner JA; Ackerman ME; Arita M; Oberste MS; Weldon WC; Sáez-Llorens X; Bandyopadhyay AS; Wright PF
    J Infect Dis; 2018 Jan; 217(3):371-380. PubMed ID: 29304199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.
    White JA; Blum JS; Hosken NA; Marshak JO; Duncan L; Zhu C; Norton EB; Clements JD; Koelle DM; Chen D; Weldon WC; Oberste MS; Lal M
    Hum Vaccin Immunother; 2014; 10(12):3611-21. PubMed ID: 25483682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
    He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
    Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules.
    Bandyopadhyay AS; Asturias EJ; O'Ryan M; Oberste MS; Weldon W; Clemens R; Rüttimann R; Modlin JF; Gast C
    Vaccine; 2017 Dec; 35(52):7283-7291. PubMed ID: 29150209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
    Sutter RW; Bahl S; Deshpande JM; Verma H; Ahmad M; Venugopal P; Rao JV; Agarkhedkar S; Lalwani SK; Kunwar A; Sethi R; Takane M; Mohanty L; Chatterjee A; John TJ; Jafari H; Aylward RB
    Lancet; 2015 Dec; 386(10011):2413-21. PubMed ID: 26388534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania.
    Bandyopadhyay AS; Gast C; Brickley EB; Rüttimann R; Clemens R; Oberste MS; Weldon WC; Ackerman ME; Connor RI; Wieland-Alter WF; Wright P; Usonis V
    J Infect Dis; 2021 Jan; 223(1):119-127. PubMed ID: 32621741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.
    Taniuchi M; Famulare M; Zaman K; Uddin MJ; Upfill-Brown AM; Ahmed T; Saha P; Haque R; Bandyopadhyay AS; Modlin JF; Platts-Mills JA; Houpt ER; Yunus M; Petri WA
    Lancet Infect Dis; 2017 Oct; 17(10):1069-1079. PubMed ID: 28693854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.
    Lopez-Medina E; Melgar M; Gaensbauer JT; Bandyopadhyay AS; Borate BR; Weldon WC; Rüttimann R; Ward J; Clemens R; Asturias EJ
    Vaccine; 2017 Jun; 35(28):3591-3597. PubMed ID: 28455172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
    Resik S; Tejeda A; Mach O; Fonseca M; Diaz M; Alemany N; Heng Hung L; Aleman Y; Mesa I; Garcia G; Sutter RW
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S51-S56. PubMed ID: 30376088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.
    Qadri F; Akhtar M; Bhuiyan TR; Chowdhury MI; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Lundgren A; Wiklund G; Kaim J; Löfstrand M; Carlin N; Bourgeois AL; Maier N; Fix A; Wierzba T; Walker RI; Svennerholm AM
    Lancet Infect Dis; 2020 Feb; 20(2):208-219. PubMed ID: 31757774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.
    Wright PF; Connor RI; Wieland-Alter WF; Hoen AG; Boesch AW; Ackerman ME; Oberste MS; Gast C; Brickley EB; Asturias EJ; Rüttimann R; Bandyopadhyay AS
    Lancet Infect Dis; 2016 Dec; 16(12):1377-1384. PubMed ID: 27638357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.